/term/inventory-turnover/TSE:4583 Chiome Bioscience (TSE:4583) Inventory Turnover
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiome Bioscience Inc (TSE:4583) » Definitions » Inventory Turnover

Chiome Bioscience (TSE:4583) Inventory Turnover : 1.18 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Chiome Bioscience Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Chiome Bioscience's Cost of Goods Sold for the three months ended in Mar. 2024 was 円72.6 Mil. Chiome Bioscience's Average Total Inventories for the quarter that ended in Mar. 2024 was 円61.6 Mil. Chiome Bioscience's Inventory Turnover for the quarter that ended in Mar. 2024 was 1.18.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Chiome Bioscience's Days Inventory for the three months ended in Mar. 2024 was 77.32.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Chiome Bioscience's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.47.


Chiome Bioscience Inventory Turnover Historical Data

The historical data trend for Chiome Bioscience's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chiome Bioscience Inventory Turnover Chart

Chiome Bioscience Annual Data
Trend Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.91 3.02 3.92 4.32 4.19

Chiome Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.01 1.15 1.13 1.10 1.18

Chiome Bioscience Inventory Turnover Calculation

Chiome Bioscience's Inventory Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Inventory Turnover (A: Dec. 2023 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2023 ) / ((Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count )
=283.869 / ((71.478 + 64.107) / 2 )
=283.869 / 67.7925
=4.19

Chiome Bioscience's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover (Q: Mar. 2024 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Mar. 2024 ) / ((Total Inventories (Q: Dec. 2023 ) + Total Inventories (Q: Mar. 2024 )) / count )
=72.646 / ((64.107 + 59.005) / 2 )
=72.646 / 61.556
=1.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chiome Bioscience  (TSE:4583) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Chiome Bioscience's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory =Average Total Inventories (Q: Mar. 2024 )/Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=61.556/72.646*365 / 4
=77.32

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Chiome Bioscience's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=61.556 / 129.644
=0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.


Chiome Bioscience Inventory Turnover Related Terms

Thank you for viewing the detailed overview of Chiome Bioscience's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Chiome Bioscience (TSE:4583) Business Description

Traded in Other Exchanges
N/A
Address
Sumitomo Fudosan Nishi-shinjuku Building No.6, 3-12-1, Honmachi, Shibuya-ku, Tokyo, JPN, 151-0071
Chiome Bioscience Inc is a Japanese based company engaged in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library System. The business activity of the group is operated through Drug Discovery Alliance, Lead Antibody Licensing, and Licensing Out Platform Technology segments. The Drug Discovery Alliance segment partners with pharmaceutical companies to develop and create lead antibody drugs. The Lead Antibody Licensing Out segment is engaged in the production of specific antibodies against antigens and early licensing out to pharmaceutical manufacturers and the Licensing Out Platform Technology segment conducts research and development through the ADLib System. Geographically all the activities are functioned through Japan.

Chiome Bioscience (TSE:4583) Headlines

No Headlines